|
Corporate News
10-May-24
|
|
|
|
|
|
|
Lupin commences shipment of Mirabegron ER Tablets to US
|
|
|
|
Lupin announced that the US Court has lifted the Temporary Restraining Order and denied Astellas' request for a preliminary injunction on Mirabegron ER Tablets. Thereafter, shipment of the
product has now resumed.
Mirabegron ER Tablets, 25 mg are a generic equivalent of Myrbetriq® Extended-Release Tablets, 25 mg of Astellas Pharma Global Development, Inc., and were launched by Lupin in April 2024.
|
|
Previous News |
Lupin’s USA facility gets 6 USFDA observations
(
Hot Pursuit
-
20-May-24
09:03
)
|
|
Lupin achieves ISO 14001 and ISO 45001 certification
(
Corporate News
-
15-May-24
18:12
)
|
|
Stock Alert: Indegene, Wipro, Biocon, HUDCO
(
Market Commentary
-
Stock Alert
13-May-24
08:28
)
|
|
Lupin grants 5,000 stock options under ESOP
(
Corporate News
-
10-May-24
17:55
)
|
|
Lupin commences shipment of Mirabegron ER Tablets to US
(
Corporate News
-
10-May-24
17:51
)
|
|
Lupin appoints Jeffrey Kindler and Alfonso Zulueta as Independent Directors on its Board
(
Corporate News
-
09-May-24
11:22
)
|
|
Lupin
(
Results
-
Analysis
07-May-24
11:15
)
|
|
Nifty ends near 22,300; realty shares tumbles
(
Market Commentary
-
Quick Review
07-May-24
15:53
)
|
|
Lupin slides as Q4 PAT drops 41% QoQ to Rs 359 cr
(
Hot Pursuit
-
07-May-24
12:02
)
|
|
Board of Lupin recommends final dividend
(
Corporate News
-
07-May-24
10:10
)
|
|
Benchmarks edge higher; breadth positive
(
Market Commentary
-
Mid-Session
07-May-24
09:41
)
|
|
|
|
Other Stories |
|
|
|
|
|
|
|
|